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ABSTrACT
To assess the correlation between the clinical and molecular assays in identify early and robust prostate cancer detection. Early detection, management 
of cancer and decision about the disease are important for beneficial treatment of prostate cancer. We used a computerized search of the Medline/
PubMed databases with the key words prostate cancer, biomarker, and early detection. Clinical management of cancer is facilitated by a conventional 
test such as prostate-specific antigen and digital rectal exam for application in clinical practice. Although these tests have significantly reduced the 
mortality with prostate cancer, but have some drawbacks and false positive rate. Fortunately, there are strong correlations between the clinical and 
molecular assays in identifying early and robust cancer detection, because molecular assays are less invasive and reliable. The use of genetic markers 
has the potential to providing useful prognostic or predictive information into clinically useful diagnostic tests to improve clinical decision-making 
and enhance therapeutic success. Different clinical and molecular assays are for detecting prostate cancer and use the biomarkers as potential tumor 
markers could be a useful predictor in the screening and monitoring to avoid over treatment prostate cancer.
Keywords: Prostate cancer, Biomarker, Clinical assay, Molecular assay.
INTroDUCTIoN
Common prostate disease includes benign prostatic hyperplasia (BPH), 
prostatitis and prostate cancer. Prostate cancer is the second type of 
cancer in men (aged 65-79 years) [1]. In fact, about 60% of all prostate 
cancers are diagnosed in men over the age of 66 years, and 97% are 
diagnosed in men at 50 years. The roles of race, age, family history, and 
diet are critical factors for developing prostate cancer [2,3]. Men of black 
African-Caribbean origin are 60% more to get prostate cancer compared 
with white Caucasian men [3]. Asian men have a lower risk than white 
men [4]. There is also the higher incidence of men with a relative history 
(father, brother, or relative with breast cancer) now or in the past to 
develop the disease. This studies have shown that Asian men have a 50% 
lower incidence of prostate cancer than Caucasian men. Furthermore, the 
influence of social and environmental factors, particularly a diet high in 
animal fat and protein and lifestyle condition increase the risk of prostate 
cancer in men [4,5]. The result of meta-analysis by Raslau et al. described 
the male flight attendants, civil and military pilots are at least 2-fold increase 
the risk of prostate cancer, compared with other people [6]. Physical 
and chemical occupational exposures, cosmic radiation and disruption 
sleep patterns are the critical factors for types of cancers among flight 
personnel [6-8]. The recent discovery of inherited and acquired genetic 
a marker has the potential to aid with cancer initiation and progressions 
provide an opportunity to understanding this heterogeneous disease and 
apply these findings to guide clinical decision-making.
lITerATUre reVIeW
We used the Medline/PubMed databases of the National Library 
of Medicine for the comprehensive information on the clinical and 
molecular procedures for prostate cancer detection. The terms used for 
the search included prostate cancer, biomarker, early detection, and the 
combinations of these terminologies.
Diagnosis and detection
Prostate as a singular organ grows with the glandular region in human 
and primates. It has heterogeneous nature and many genes involved 
in prostate cancer development. Prostate cancer cells often grow and 
divide abnormally within the prostate. Most of the cancers have been 
classified into four stages [9]. In some case, the cancer cells grow 
more quickly and may spread to other parts of the body. There are 
several clinical tests for the diagnosis of prostate cancer. The prostate-
specific antigen (PSA) blood test, digital rectal exam (DRE), magnetic 
resonance imaging, and sonography are the first-line options to detect 
the presence of prostate cancer when no problems or symptoms are 
present [10]. Sonography appears to be a very important that can 
be performed on patients without any side effect or radiation. These 
tests allow experimental approaches for reducing the number men 
presenting with metastatic cancer [11]. During a DRE, doctors can 
examine the prostate for any irregularities in shape, size, and outline of 
the prostate. During a PSA test, the level of PSA, a protein produced by 
the prostate is measured by a monoclonal immunoradiometric assay or 
a polyclonal radioimmunoassay. For the first time in 1991, Catalona and 
colleagues applied the PSA screening for detection prostate cancer [12]. 
PSA is found in blood plasma at low levels but can increase in prostatic 
disease. PSA levels are correlated with prostate cancer and can be 
measured from a small of peripheral (venous) blood. PSA blood levels 
under 4 ng/ml are usually normal; results between 4 and 10 ng/ml 
are intermediate and results over 10 ng/ml are considered high [13]. 
Clinicians recommend that both PSA and DRE should be confirmed 
annually at age 40 and older without any symptoms. Although these 
tests cannot diagnose prostate cancer specifically, the way to determine 
for prostate cancer cells is a prostate biopsy. The PSA and DRE can 
determine the need for doing a biopsy [14]. Transrectal or transperineal 
ultrasound guide biopsies with a probe placed in the rectum to collect 
the small tissue samples [15]. If prostate cancer is found under the 
microscope, the pathologist assigns it by Gleason scores. Gleason grade 
is used in clinical predicators of cancer progression for measuring the 
degree of differentiation of tumor cells. On scores from (2-4) tend to 
low grade; Gleason scores (5-6) middle grade and Gleason scores (7-10) 
tend to be more aggressive. Men with low-grade Gleason ≤6 tumors 
have a low risk of metastasis, and Gleason ≥7 have a high risk of lethal 
prostate cancer significantly. Staging can describe the extent of the 
prostate cancer and provide an idea of management and treatment. 
Types of prostate cancer are; localized prostate, locally advanced, 
and metastatic. Localized prostate cancer is located only within the 
prostate. In locally advanced the most cancer cells are within the 
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prostate, but some cells are growing outside the prostate and escape 
to the surrounding tissue and cancer can spread from the prostate to 
nearby tissue such as bladder or rectum. Metastatic cancer, the cells 
are growing outside the prostate and spread to other areas in the body 
into the lymph nodes or bone. A rapid diagnosis of cancer is critical for 
the clinician to the immediate initiation of treatment [16]. There are 
several major treatment options for a patient diagnosed with localized 
or locally advanced prostate cancer; active surveillance, surgery, 
radiotherapy, and hormone therapy. During active surveillance, cancer 
can be monitored exactly to developing of signs.
Radiation therapy is used two different ways; to cure cancer, destroy 
tumors that have not spread to other body parts; to reduce symptoms, 
alleviate pain by reducing the size of a tumor. Radiation can be delivered 
two ways; externally and internally. External radiation therapy delivers 
radiation using a linear accelerator beam and helps to kill cancer cells 
and surrounding tissue. Internal radiation called brachytherapy or seed 
implants involves placing tiny radioactive metal seeds or pellets into 
the prostate patient. Radiotherapy is combined with other treatments, 
such as surgery and chemotherapy [17]. Surgery is the effective 
treatment, while the tumor is within the prostatic capsule. A radical 
prostatectomy is the surgical removal of the entire prostate gland plus 
some surrounding tissue. At present, robotic surgery and laparoscopy 
are available [18]. In some cases, patients have experienced urinary 
continence, erectile dysfunction, and biochemical recurrence within 
5 years after surgery. The type of treatment used will depend on the 
men’s age, economic position, general health, stage, location, size, and 
type of cancer [18]. Furthermore, treatment with hormone therapy 
to lower testosterone level is typically done; this treatment stops the 
production of testosterone and can make prostate cancer grow more 
slowly [19]. However, PSA and DRE are considered the great clinical 
routinely tests by urologists for establishing and correct diagnosis; 
which have multiple limitations. PSA 2-9 ng/ml has poor correlation 
with grade and disease progression [20]. In some cases, PSA can be 
raised in BPH (overgrowth), aggressive cancers or infections or those 
are not cancerous, thus leading to a delay in diagnosis and unnecessary 
biopsies. They are lacks sensitivity and specificity [20].
Prostate cancer antigen 3 (PCA3 or DD3) is a prostate-specific 
gene [13]. In the PCA3 test, the urine collected after post-DRE and 
measures the concentration the ratio of PCA3 RNA molecules and PSA 
RNA molecules [21]. The PCA3 analysis is easily and good biomarker 
prostate cancer after DRE [13]. Prostate cancer possibly decreased 
when a PCA3 score is >25. It is suitable for men negative biopsy results 
and PSA levels and DRE are positive. Detection and treatment pathways 
in prostate cancer are shown in Fig. 1.
MoleCUlAr GeNeTIC AlTerATIoNS IN ProSTATe CANCer
The most common cancers occur by allelic variability at some 
locus. Molecular genetic alterations such as protein expression, 
chromosomal rearrangement, oncogene activation, tumor 
suppressor gene alterations, DNA mitochondrial mutations, and gene 
polymorphism in the repeat of androgen receptor are associated 
with risk of prostate cancer. Much attention lately is focused on the 
genome in populations of the major gene loci that contribute to the 
disease. Such studies use a tool neutral variation between individuals 
in DNA sequence or polymorphisms. These polymorphic markers 
are present at high density in the human genome. The previous 
studies have suggested that both environmental and genetic factors 
and individual difference in the susceptibility to carcinogens may 
be imputed to the genetic polymorphisms of genes required in the 
metabolic detoxification of exogenous and endogenous carcinogens 
and chemotherapeutic agents. There are several important genes 
such as glutathione-S-transferases (GST) which are involved in DNA 
repair and protect DNA from damages by detoxifying the carcinogens, 
metabolism of hormones and chemical agents. Different GST isoform 
is expressed in the prostate and some tissues [22-23]. Several 
genetic polymorphisms and total or partial deletions of GST family 
(GSTM1, GSTT1, GSTM3, GSTPI, and GSTZ1) have been identified that 
associated with a reduction of enzymatic activity [24]. The previous 
studies have suggested that individuals with null genotypes of GSTs 
may be unable to inactivate electrophilic carcinogens efficiently and 
higher risk for prostate cancer [25]. An additional finding was that 
GSTM1 null genotypes were significantly 45.5% higher in cancer and 
BPH group compare with normal men. In cohort studies Cotignola 
et al. have demonstrated that more than two polymorphism alleles 
of GSTs (GSTM1 null, GSTT1 null, and GSTP1 A>G) were at high risk 
for relapse after radical prostatectomy in Argentina patients [16]. 
These results are consistent with the finding of reported in Caucasian 
men by Nock et al [26]. The GSTP1 genes are down-regulated in 
prostate carcinogenesis. This gene is involved in the detoxification 
of electrophilic carcinogens and has a polymorphic site at codon 105 
(exon 5), where (A>G) transition causes an Ile-to-Val substitution. 
The presence of valine residue to the hydrophobic binding site for 
electrophilic substrates has been associated with decreased enzyme 
activity and a tendency to increase neoplasms [22]. Knowledge of 
GST variation has led to understanding the role of GST family genes 
in somatic mutation and tumor formation [16]. Other the most 
frequently mutated genes are p53 and ki-67 [20]. p53 mutations 
are present in half of the tumors [27]. The p53 plays a critical role 
in human cancer as a transcription factor in cell cycle progression 
and DNA damage or cellular stress. The lack of p53 leads to cell 
cycle arrest and apoptosis. Furthermore, the novel role of ki-67 in 
a regulation of the cell cycle and a nuclear antigen was identified. A 
high-level Ki-67 expression is a prognostic marker of prostate cancer 
recurrence after radical prostatectomy [28]. In a study by Verma 
and colleagues were observed both p53 and ki-67 expression were 
significantly up-regulated in malignant prostate cancer as compared 
to benign tissue and relation with Gleason’s grading [28,29]. These 
results give support to the use of these marker genes together for 
personalized medicine as an ideal marker for cancer management.
MIToChoNDrIAl DNA IN ProSTATe CANCer
Any type of tests can be identified by mutations in the mitochondrial 
genome in different cancer [30]. For the first time, Jeronimo et al. 
have also demonstrated the presence of tumor specific mitochondrial 
genome in the plasma and tumoral tissue from prostate cancer 
patients [30]. Tumor cells contain thousands of copies of double-
stranded DNA in the inner mitochondrial matrix. Therefore, the 
presence of highly copy number is quite specific way to increase the 
sensitivity of early detection. In some cases, mutation within protein 
coding regions in NADH dehydrogenase subunits 3-5 from complex 1 
is the hotspot in cancer. D-loop is a regulatory site for both replication 
and expression of mitochondrial DNA. D-loop mutations are identified 
in many body fluids due to high copy number as a diagnostic tool in 
neoplastic tissue. D-loop variations and microsatellite instability can 
influence cell physiology and result in a benign or malignant phenotype 
in cancer patients [31]. Various studies have shown that the number of 
CAG repeat ≤21 inpatients with prostate cancer was smaller than BPH 
and normal group. Balic and coworkers showed the number of CAG ≤18 
have 3-fold higher risk for prostate cancer in Hispanic men [31]. 
Furthermore, some investigations have confirmed in China and Indian 
populations; polymorphic CAG repeats gene associated with high-risk 
cancer.
MIrNA IN ProSTATe CANCer
Mendel and Matais reported that extracellular nucleic acid could 
be detected from healthy and sick individuals. Nucleic acids as a 
tumor marker have been developed for the purpose of screening for 
early malignant diseases and monitoring cancer progression. Some 
tumor markers (mRNA, microRNA, and proteins) are detectable to 
differentiate between normal and cancer tissue [32,33].
Although proteins have significantly identified of biomarker science, 
there are several drawbacks such as methods of detection, availability, 
and stability. General techniques for measurements of protein 
biomarkers antigen–antibody complex formation are detected by ELISA 
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test. MRNA expression has been suggested as a potential marker for 
detection of prostate cancer. 
A miRNAs have been identified as new generations of biomarkers 
not only to be developed into sensitive and robust markers but also 
to monitor disease progression and efficacy of treatment [34]. Using 
current the public database miRBase, 2500 mature miRNA have 
been discovered. They are ideal candidates for innovating new early 
detection and diagnosis for cancer [1,34,35]. A miRNAs are a group of 
small noncoding RNA molecules that are transcribed by polymerase II 
to producing the primary miRNA (pre-miRNA). Subsequently, RNase III 
generates precursor (pre-miRNA) with 70-100 nucleotides. Then, pre-
miRNA is exported to the cytoplasme, and Dicer enzyme cleaves the 
miRNA into 22 nucleotides in length [36-38]. Different miRNAs with the 
capacity regulate gene expression through binding to complementary 
sequences in the 3’-untranslated region of the target gene [39]. 
Interestingly, some microRNAs have multiple targets, and some others 
can be targeted by several miRNA. Approximately 52% of miRNA genes 
are located the intergenic area, 40% are within introns, and 8% are 
within exons.
Today’s, several reports have indicated that miRNAs are present in 
other fluids such as serum, blood, saliva, sputum, amniotic fluid, urine, 
and plasma [40,41]. Serum or plasma studies showed up-regulated of 
miR-375, miR-141, miR-21, miR-93, miR-106a, miR-874, miR-1207, and 
miR-26 in patients with prostate cancer [42]. With this idea, miRNA can 
be released into the blood in stable form and are highly effective manner, 
noninvasive diagnosis and predictable the response to therapy [32,43]. 
Urine is even more accessible than blood, and larger sample volumes 
can be obtained [41]. Urinary biomarkers can be detected from the 
bloodstream [41]. These small molecules persist for a long time 
because of the stable miRNA-protein or miRNA-lipid complexes. A 
miRNA molecules could play important roles in differential expression, 
inflammation, proliferation, cell cycle, apoptosis, cancers initiation, 
progression, metastases, and drug resistance [1]. The first report was 
in 2007 by Valadi et al. also showed the encapsulation of miRNAs into 
exosome bodies and can be secreted into blood circulation [44,45]. The 
exosome is a secreted vesicle that attached to the surface of acceptance 
cells and enters the cells via endocytosis, which regulates cell to cell 
communication and release miRNAs. Extracellular microRNAs in 
circulating exosomes are robust biomarkers in cancer. Higher exosomal 
miR-141 is significantly associated with metastatic prostate cancer and 
also a high-level exosomal expression of miR-1290 and miR-375 are 
associated with cancer progression [42].
In patients with prostate cancer, tissue samples down-regulated in 
5 miRNAs (miR-23b, miR-100, miR-145, miR-221, and miR-222), 
whereas miR-135-b, miR-194 were increased [46,47]. Recently, some 
miRNAs expressions were shown to be significantly correlated with 
the Gleason scores and tumor stage. In fact, down-regulated circulating 
levels of miR-221 were associated with Gleason score, progression 
and recurrent. Penney and coworkers found 157 mRNA expressions 
in prostate cancer could be used to predict both Gleason score and 
the relative risk of lethality [48]. Some evidence has shown the role of 
miRNAs as an oncogene or tumor suppressor gene in cancer initiation, 
lymph node metastasis, progression, and drug resistance in the type of 
cancer [49]. MiR-21 (17q23), as an oncogene, is the most frequently 
in the development of many types of human cancers and in prostate 
cancer and patient follow-up [50-52]. Some studies reported that 
invasive tumors have over expression of miR-21 by targeting PTEN, 
TPM1, and PDCD4 genes in prostate cancer specimens [53,54]. The 
expression levels of miR-21, miR-125b, and miR-141 were highly 
expressed in prostate cancer as oncogenesis [55,56]. Some microRNAs 
such as miR-15, miR-16, miR-31, miR-330, miR-145, miR-146a, 
miR-203, and miR-205 expression were significantly down-regulated 
as tumor suppressor gene in prostate cancer.
In 2011, Cuzick et al. showed that cycle cell progression scores and 
PSA levels are involved in the relative risk of mortality and avoid to 
over-treatment, especially unnecessary surgery and biopsies [57]. 
Volinia et al. reported upregulation of miRNAs (miR-17-5p, miR-21, 
miR-25, miR-30c, miR-146, miR-181b-1, miR-199a-1, miR-29b-2, miR-
20a, miR-32, miR-92, and miR-214) in prostate cancer and 6 miRNAs 
downregulation in their study [58]. Importantly, Ambs et al. found that 
miR-26a, miR-32, miR-196a, miR-181a, miR-25, miR-92, miR-93, Let-7i 
expression are increased in prostate cancer cells compared to normal 
cells and also determined some miRNAs correlated with androgen 
regulation, which is similar to Volinia and coworkers findings [58,59]. 
In another study, Porkka et al. and Ozen et al. found downregulation 
of miR-23, miR-29, miR-99, miR-125, miR-30, Let-7 family in prostate 
cancer tissue [36,46]. According to Brase et al., circulating miR-375 
and miR-141 levels correlated with high Gleason score and spread to 
lymph node [60]. Interestingly, miR-375 plays the dual role in prostate 
carcinogenesis and progression. In patients with the higher Gleason 
fig. 1: Detection and treatment options for prostate disease
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score and lymph nodes metastases significantly higher expression 
levels of miR-375 were observed, whereas in PC-3 cells the level of miR-
375 was down-regulated [1]. Moreover, CCND2 was identified as the 
miR-375 target in prostate cancer. MiR-375 and CCND2 are involved in 
cell cycle regulation. Furthermore, in patients with metastatic prostate 
cancer, miR-375 is significantly up-regulated in serum exosome relative 
to those of patients without non-recurrent prostate cancer. Many 
studies reported that miR-143 and miR-145 are very important in 
the development of prostate cancer and advanced disease stage [61]. 
Upregulation miR-96 and downregulation miR-221 is associated with 
the Gleason score and recurrent after surgery. Therefore, noninvasive 
assays are appropriated for use in clinical that are reliable and 
inexpensive.
CoNClUSIoN
Cancer is a complex disease and difficult to diagnoses and treat. Prostate 
diseases in humans may arise through a combination of basic processes 
of tissue changes and the sum of genetic and environmental risk factors 
to which the individual is exposed. Together, these determine the 
individual disease risk.
Many studies are currently being focused on the dissection of genetic 
influences on common complex diseases such as cancer disease. The 
genetic make-up of individuals contributes considerably to the risk 
of disease within the context of age, various systemic risk factors, 
lifestyle and an environment. The approach of genome searching 
allows for identification of yet unknown genes with a major effect the 
pathophysiology of cancer disease.
Early detection is the best method of combating cancer and can be 
treated successfully. Whereas, advanced cancer is difficult to treat and 
has a poor prognosis. Early prostate cancer usually has no symptoms 
but can be characterized by molecular genetic markers and clinical 
screening. Identification of patients who have increased familiar 
incidence of cancer and gremlin mutation is the most importance. 
In this regards, teamwork collaboration with clinicians, geneticists, 
pathologists and epidemiologists to identify clinical and pathology 
features without morbidity provide unique opportunities for patient’s 
decision making.
Development of new molecular approaches is the most promising way 
to reducing mortality. Molecular biomarkers in clinical oncology have 
described as a group of detectable and characteristic alterations in 
DNA and proteins. The connection between molecular detections and 
clinical tests is the direct one to understanding the prostate cancer 
onset and progression. Biomarkers are an interesting and promising 
marker to improve outcomes while reducing the overtreatment of 
disease. Therefore, identification of more reliable and sensitive marker 
than PSA and DRE is emerging. Other techniques are time-consuming 
or less attractive for routine monitoring. The studies performed to 
date mainly focused on detection and applicability of biomarker. A 
few studies focused on quantification methods, searching for fast, easy 
methods that are widely applicable in clinical practice. Although several 
limitations impede the clinical implementation of the biomarker until 
now such as information related to sample collection, the time between 
collection and processing and storage time.
The knowledge about biomarkers that are released outside the cell, 
abundant expression, board dynamic range, amplifiable signals and 
some qualities that make them attractive candidates. Circulating DNA, 
miRNAs, and mRNA can be correlated with Gleason score, metastases 
to other organs, susceptibility and predict recurrence disease. Urinary 
and tissue biomarkers and gene assays allow patient specific molecular 
and genetic characterization of cancer phenotype; will likely become 
incorporated into major oncologic guidelines and standard urologic 
practice.
Furthermore, they help to increase the quality of life and choosing the 
best treatment for optimization of personalized medicine and response 
to therapy. We hope that advances in science and further extensive 
studies are necessary to solve these problems in health-care system.
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